Sarcomas/TGCT | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Current Management Strategies for Desmoid Tumors Are Marked by Less Surgery, More Systemic Options

December 20th 2021

Despite their rarity, the management of desmoid tumors has been an area of significant clinical change as the field has shifted away from aggressive surgical interventions to active surveillance and systemic therapies that are less morbid for patients.

Enrollment in Histologically-Specific Trials Improves Outcomes in Soft Tissue Sarcoma

December 16th 2021

Elise Nassif, MD, discusses the evolving standard of care for patients with soft tissue sarcoma and the benefits of early phase inclusion, as well as histotype testing for this population.

VTC Plus Standard Chemotherapy Fails to Improve EFS and OS in Ewing Sarcoma

December 16th 2021

R. Lor Randall, MD, FACS, elaborates on the results of a study and provided insight into future research directions in Ewing sarcoma

Dr. Randall on the Evolution of Limb Salvage Technologies in Bone Sarcomas

December 10th 2021

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

Ribociclib/Everolimus Elicits Responses in Dedifferentiated Liposarcoma

December 5th 2021

Margaret von Mehren, MD, discusses the value of ribociclib plus everolimus for patients with dedifferentiated liposarcoma, and how further research will be focused on biomarker analysis.

ONCT-216 Shows Encouraging Efficacy, Safety in Relapsed/Refractory Ewing Sarcoma

November 24th 2021

The targeted small molecule inhibitor of the E26 transformation-specific family of oncoproteins, ONCT-216, produced notable response and disease control rates when delivered at the recommended phase 2 dose to heavily pretreated patients with Ewing sarcoma.

FDA Approves Sirolimus Protein-Bound Particles for Malignant PEComa

November 23rd 2021

The FDA has approved sirolimus albumin-bound particles for injectable suspension for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.

Dr. Wilky on the Diagnosis and Management of Desmoid Tumors

November 19th 2021

Breelyn Wilky, MD, discusses the diagnosis and management of desmoid tumors.

NBTXR3 Plus Radiotherapy Maintains Safety, Quality of Life in Soft Tissue Sarcoma

November 19th 2021

Sylvie Bonvalot, MD, PhD, HDR, discusses the long-term safety results from the phase 2/3 Act.In.Sarc trial with NBTXR3 and radiotherapy in patients with soft tissue sarcoma.

Compressive Osseointegrated Endoprostheses Provide Long-Term Benefit in Bone Sarcoma

November 18th 2021

R. Lor Randall, MD, FACS, the 10-year results of a retrospective analysis, potential strategies to mitigate early failures in recipients of compressive osseointegrative endoprosthetic devices, and the need for communication between medical oncologists and orthopedic surgeons to ensure patients on chemotherapy receive optimal care.

Dr. D’Amato on Optimizing Treatment for Patients With Desmoid Tumors

November 18th 2021

Gina Z. D’Amato, MD, discusses optimizing treatment for patients with desmoid tumors.

Dr. Riedel on the Challenges of Diagnosing and Treating Patients With Desmoid Tumors

November 18th 2021

Richard F. Riedel, MD, discusses the challenges of diagnosing and treating patients with desmoid tumors.

Ripretinib Continues to Provide Meaningful Clinical Benefit in Heavily Pretreated GIST

November 10th 2021

John R. Zalcberg, MBBS, PhD, discusses the INVICTUS trial examining ripretinib in patients with heavily pretreated gastrointestinal stromal tumors, the impact of the agent on the paradigm, and ongoing efforts to provide additional options to this population.

Pembrolizumab/Lenvatinib Combo Under Investigation in Classic Kaposi Sarcoma

November 9th 2021

Alice Indini, MD, discusses the ongoing PULSAR trial examining pembrolizumab plus lenvatinib as a novel therapeutic option for patients with classic Kaposi sarcoma.

Ripretinib Misses PFS End Point in Second-Line Gastrointestinal Stromal Tumor

November 5th 2021

Ripretinib did not significantly improve progression-free survival over sunitinib in patients with gastrointestinal stromal tumor who previously received imatinib, missing the primary end point of the phase 3 INTRIGUE trial.

Varying Pathological Features Needed to Determine Prognosis in Myoepithelial Tumors

November 2nd 2021

There is significant clinical, pathological, and outcome heterogeneity in myoepithelial tumors and prognoses for these tumors cannot be determined by a single pathological feature, but rather, several patient and tumor characteristics.

Dr. Randall on Initial Considerations When Treating Patients With Desmoid Tumors

October 26th 2021

R. Lor Randall, MD, FACS, discusses initial considerations when treating patients with desmoid tumors.

Annamycin Showcases Early Clinical Activity in Soft Tissue Sarcoma Lung Metastases

October 26th 2021

Treatment with the next-generation anthracycline annamycin was found to result in preliminary clinical activity without dose-limiting toxicities in patients with soft tissue sarcoma lung metastases.

Risk-Stratification Can Be Used to Prevent Overtreatment in Children, AYA Patients With Synovial Sarcoma

October 25th 2021

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

Dr. Van Tine on Next Steps With Catequentinib in Soft Tissue Sarcoma

October 14th 2021

Brian A. Van Tine, MD, PhD, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma.